

Part D Counseling Called an 'Unfunded Mandate'

BY NELLIE BRISTOL
Contributing Writer

WASHINGTON — Physician obligation to help patients negotiate the upcoming Medicare Part D outpatient drug benefit will result in "another unfunded mandate" for Medicare providers, Ronald Castellanos, M.D., chairman of the Practicing Physicians Advisory Council said at the group's recent meeting.

Noting that patients are most likely to rely on their physicians for aid in choosing among the new drug plans, Dr. Castellanos said, "Basically what you're doing is putting the burden on physicians in their offices to really educate the Medicare recipient."

PPAC members asked the Centers for Medicare and Medicaid Services to make educational materials as simple as possible, including information on whether beneficiaries are eligible for the low-income portion of the program.

"I really want a lot of information, very digestible," said PPAC member Geraldine O'Shea, D.O., an internist from Jackson,

PPAC members asked CMS to make educational materials as simple as possible, with information on eligibility for the program's low-income portion.

Calif. "Something very easy for them to understand, because I do not want to take time out of my time to do medicine with my patient to say, 'Well, let me see your tax return.'"

"We are trying to make the information

available as simple as possible," said Jeffrey Kelman, M.D., medical officer for the CMS Center for Beneficiary Choices, noting that he would bring educational material to the council's next meeting.

Council member Barbara McAneny, M.D., an oncologist from Albuquerque, requested that the agency develop a computer program that would allow physicians to type in the drugs a patient is using and come up with the plan that would cover all of them.

She also proposed a draft recommendation that would require CMS to develop a reimbursement code for physician time spent on drug plan education, but it was voted down by the panel, with members saying it wasn't practical.

Walking through the benefit, Dr. Kelman said CMS is getting "much more robust formularies" from drug plans than officials had anticipated. "They're looking like commercial formularies," he said. He added that the formularies would be available on the Web site in October.

All drugs approved by the Food and Drug Administration must be on the formularies, Dr. Kelman said. If a drug is not included, a beneficiary can appeal, based on medical necessity, but "preferably with a physician's help," he said.

"All medically necessary drugs that are approved by the FDA with certain exceptions ... have to be available." Off-label prescriptions will be covered, Dr. Kelman said.

In a move important to rare drug organizations, Dr. Kelman said if there is only one drug to treat a disease, it must be included in the formulary.

Part D also will ensure drugs are available for chronic conditions by "favorably risk adjusting" those diseases, Dr. Kelman said. The plans also will "overadjust" for low-income individuals and nursing homes. "We went to a lot of trouble to ensure nobody was discriminated against on the formulary or based on the Part D

benefit," Dr. Kelman said. He said formularies would be compared to others in their region and to commercial plans.

Council member Laura Powers, M.D., a neurologist from Knoxville, Tenn., said she was relieved by Dr. Kelman's comments. "We were so worried that our patients with very expensive drugs were going to be eliminated from all the formularies."

Dr. Kelman urged physicians to begin moving patients to the new formularies before the benefit is effective Jan. 1, 2006.

"The last thing we want is 40 million exceptions and appeals in the first week," he said. Beneficiaries can enroll in the program from Nov. 15 through May 15.

Dr. Kelman pointed out that by law, barbiturates and benzodiazepines will not be covered by the plans. He said the hope is that states will continue to pay for them for beneficiaries on both Medicaid and Medicare. Also not covered are cosmetic agents and weight-loss and weight-gain products. ■

For maintenance therapy of bronchospasm in COPD—

SPIRIVA HandiHaler: Inspire your COPD patients with

Sustained Efficacy

All Day, Every Day

SPIRIVA sustained lung function improvement through 1 year¹



SPIRIVA HandiHaler is indicated for the long-term, once-daily, maintenance treatment of bronchospasm associated with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

SPIRIVA HandiHaler is not indicated as a rescue medication and is contraindicated in patients with a history of hypersensitivity to atropine or its derivatives, i.e., ipratropium, or to any component of this product.

The most commonly reported adverse drug reaction was dry mouth, which was usually mild and often resolved during continued treatment.

Reference: 1. Data on file, Boehringer Ingelheim Pharmaceuticals, Inc.
Please see brief summary of Prescribing Information on adjacent page.

Once-Daily
SPIRIVA[®] HandiHaler[®]
(tiotropium bromide inhalation powder)



OPEN UP AND BREATHE™